partner and localizer of BRCA2Genealiases: BROVCA5 · FANCN · PNCA3
Q-omics provides the consensus-scored PALB2 profile across patient tissues and cancer cell-line models. PALB2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, PALB2 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, PALB2 RNA expression shows 21,130 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight READ, HNSC, and ACC as cancer lineages where PALB2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PALB2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PALB2 survival associations across molecular data types. PALB2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PALB2 RNA expression–survival associations across cancer types. High PALB2 expression shows unfavorable associations in PAAD, but favorable associations in READ, KIRC, HNSC, ESCA and COAD. The READ Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify READ as the clearest survival context for PALB2 RNA expression.
This table summarizes PALB2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for PALB2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PALB2 shows higher tumor expression in HNSC, BLCA, KIRP, COAD, KIRC and LIHC. The HNSC box plot shows higher PALB2 RNA expression in tumor versus normal tissue (log2 FC = +1.014, t-test p < 0.001).
This table shows molecular features associated with PALB2 in patient tissues and cancer cell lines. In patient samples, PALB2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PALB2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
